These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 18789710)

  • 21. Application of liquid chromatography-accelerator mass spectrometry (LC-AMS) to evaluate the metabolic profiles of a drug candidate in human urine and plasma.
    Prakash C; Shaffer CL; Tremaine LM; Liberman RG; Skipper PL; Flarakos J; Tannenbaum SR
    Drug Metab Lett; 2007 Aug; 1(3):226-31. PubMed ID: 19356047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitating isotopic molecular labels with accelerator mass spectrometry.
    Vogel JS; Love AH
    Methods Enzymol; 2005; 402():402-22. PubMed ID: 16401517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug detection in urine by chemical ionization mass spectrometry.
    Saferstein R; Manura JJ; De PK
    J Forensic Sci; 1978 Jan; 23(1):29-36. PubMed ID: 744965
    [No Abstract]   [Full Text] [Related]  

  • 24. In vitro evaluation of new biocompatible coatings for solid-phase microextraction: implications for drug analysis and in vivo sampling applications.
    Vuckovic D; Shirey R; Chen Y; Sidisky L; Aurand C; Stenerson K; Pawliszyn J
    Anal Chim Acta; 2009 Apr; 638(2):175-85. PubMed ID: 19327457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts.
    Garner RC; Barker J; Flavell C; Garner JV; Whattam M; Young GC; Cussans N; Jezequel S; Leong D
    J Pharm Biomed Anal; 2000 Dec; 24(2):197-209. PubMed ID: 11130199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Applications of accelerator mass spectrometry for pharmacological and toxicological research.
    Brown K; Tompkins EM; White IN
    Mass Spectrom Rev; 2006; 25(1):127-45. PubMed ID: 16059873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The gas chromatograph-mass spectrometer as a new and important tool in forensic toxicology.
    Skinner RF; Gallaher EJ; Knight JB; Bonelli EJ
    J Forensic Sci; 1972 Apr; 17(2):189-98. PubMed ID: 4679764
    [No Abstract]   [Full Text] [Related]  

  • 28. Editorial: Pre-race drug testing.
    Maylin GA
    Cornell Vet; 1974 Jul; 64(3):325-34. PubMed ID: 4845726
    [No Abstract]   [Full Text] [Related]  

  • 29. Screening for basic drugs in hair of drug addicts by liquid chromatography/time-of-flight mass spectrometry.
    Pelander A; Ristimaa J; Rasanen I; Vuori E; Ojanperä I
    Ther Drug Monit; 2008 Dec; 30(6):717-24. PubMed ID: 18806694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A microcomputer-directed mass spectrometer as a compound-selective detector for gas chromatography.
    Strauss PA; Hertel RH
    J Chromatogr; 1977 Apr; 134(1):39-48. PubMed ID: 870504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid analysis of captopril in human plasma and pharmaceutical preparations by headspace solid phase microextraction based on polypyrrole film coupled to ion mobility spectrometry.
    Karimi A; Alizadeh N
    Talanta; 2009 Jul; 79(2):479-85. PubMed ID: 19559908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sample preparation for quantitation of tritium by accelerator mass spectrometry.
    Chiarappa-Zucca ML; Dingley KH; Roberts ML; Velsko CA; Love AH
    Anal Chem; 2002 Dec; 74(24):6285-90. PubMed ID: 12510750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Automation of in-tip solid-phase microextraction in 96-well format for the determination of a model drug compound in human plasma by liquid chromatography with tandem mass spectrometric detection.
    Xie W; Mullett WM; Miller-Stein CM; Pawliszyn J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Feb; 877(4):415-20. PubMed ID: 19144575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fractional mass filtering as a means to assess circulating metabolites in early human clinical studies.
    Tiller PR; Yu S; Bateman KP; Castro-Perez J; McIntosh IS; Kuo Y; Baillie TA
    Rapid Commun Mass Spectrom; 2008 Nov; 22(22):3510-6. PubMed ID: 18853407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An interface for direct analysis of (14)c in nonvolatile samples by accelerator mass spectrometry.
    Liberman RG; Tannenbaum SR; Hughey BJ; Shefer RE; Klinkowstein RE; Prakash C; Harriman SP; Skipper PL
    Anal Chem; 2004 Jan; 76(2):328-34. PubMed ID: 14719879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative selected ion monitoring (QSIM) of drugs and/or drug metabolites in biological matrices.
    Garland WA; Powell ML
    J Chromatogr Sci; 1981 Aug; 19(8):392-434. PubMed ID: 7024291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liquid chromatography-mass spectrometry in in vitro drug metabolite screening.
    Tolonen A; Turpeinen M; Pelkonen O
    Drug Discov Today; 2009 Feb; 14(3-4):120-33. PubMed ID: 19059358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accelerator mass spectrometry at Arizona: geochronology of the climate record and connections with the ocean.
    Jull AJ; Burr GS; Beck JW; Donahue DJ; Biddulph D; Hatheway AL; Lange TE; McHargue LR
    J Environ Radioact; 2003; 69(1-2):3-19. PubMed ID: 12860086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distribution of drug screen results at the University of Nebraska Hospital in 1985.
    Huth JA
    Nebr Med J; 1986 Oct; 71(10):359-62. PubMed ID: 3774062
    [No Abstract]   [Full Text] [Related]  

  • 40. A retention-time-shift-tolerant background subtraction and noise reduction algorithm (BgS-NoRA) for extraction of drug metabolites in liquid chromatography/mass spectrometry data from biological matrices.
    Zhu P; Ding W; Tong W; Ghosal A; Alton K; Chowdhury S
    Rapid Commun Mass Spectrom; 2009 Jun; 23(11):1563-72. PubMed ID: 19408276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.